Evidence map›Paper›PMID 38986026›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

De Novo Synthesis of α-Ketoamides via Pd/TBD Synergistic Catalysis.

Jia-He Chen, Li-Ren Zhang, Zhang-Yang Wang, Lu-Jie Liu, Li-Ping Tu, Yun Zhang, Yong-Zheng Chen, Wen-Yong Han

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. De Novo Synthesis of α-Ketoamides via Pd/TBD Synergistic Catalysis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jia-He ChenKey Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, No. 6 West Xuefu Rd., Zunyi, 563006, China.
Li-Ren ZhangKey Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, No. 6 West Xuefu Rd., Zunyi, 563006, China.
Zhang-Yang WangKey Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, No. 6 West Xuefu Rd., Zunyi, 563006, China.
Lu-Jie LiuKey Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, No. 6 West Xuefu Rd., Zunyi, 563006, China.
Li-Ping TuKey Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, No. 6 West Xuefu Rd., Zunyi, 563006, China.
Yun ZhangKey Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, No. 6 West Xuefu Rd., Zunyi, 563006, China.
Yong-Zheng ChenKey Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, No. 6 West Xuefu Rd., Zunyi, 563006, China.
Wen-Yong HanKey Laboratory of Biocatalysis & Chiral Drug Synthesis of Guizhou Province, Generic Drug Research Center of Guizhou Province, Green Pharmaceuticals Engineering Research Center of Guizhou Province, School of Pharmacy, Zunyi Medical University, No. 6 West Xuefu Rd., Zunyi, 563006, China.ORCID https://orcid.org/0000-0001-6236-4238

Funding

Fifth Batch of Talent Base in Guizhou Province S-030-1Guizhou Provincial Natural Science Foundation QKHJC-2020-1Z072National Natural Science Foundation of China 21901265National Natural Science Foundation of China 22261057Science and Technology Department of Guizhou Province QKHPTRC-CXTD[2022]012Science and Technology Department of Guizhou Province QKHPTRC-GCC[2023]003Science and Technology Department of Zunyi ZSKH-2018-3Science and Technology Department of Zunyi ZSKRPT-2020-5Science and Technology Department of Zunyi ZSKRPT-2021-5Zunyi Medical University 18ZY-002Zunyi Medical University 202210661193Zunyi Medical University ZYDC2022005
6 · The paper itself

Abstract

Precisely controlling the product selectivity of a reaction is an important objective in organic synthesis. α-Ketoamides are vital intermediates in chemical transformations and privileged motifs in numerous drugs, natural products, and biologically active molecules. The selective synthesis of α-ketoamides from feedstock chemicals in a safe and operationally simple manner under mild conditions is a long-standing catalysis challenge. Herein, an unprecedented TBD-switched Pd-catalyzed double isocyanide insertion reaction for assembling ketoamides in aqueous DMSO from (hetero)aryl halides and pseudohalides under mild conditions is reported. The effectiveness and utility of this protocol are demonstrated by its diverse substrate scope (93 examples), the ability to late-stage modify pharmaceuticals, scalability to large-scale synthesis, and the synthesis of pharmaceutically active molecules. Mechanistic studies indicate that TBD is a key ligand that modulates the Pd-catalyzed double isocyanide insertion process, thereby selectively providing the desired α-ketoamides in a unique manner. In addition, the imidoylpalladium(II) complex and α-ketoimine amide are successfully isolated and determined by X-ray analysis, confirming that they are probable intermediates in the catalytic pathway.

Indexed as

double isocyanide insertionpalladium catalystsynergistic catalysisTBDα‐ketoamides

Identifiers

PMID38986026
PMCPMC11425860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.